Ozempic Knock-Offs: Are They Safe?

Compounded semaglutide, created by specialized pharmacies, is not subject to the same rigorous FDA testing as brand-name drugs like Ozempic and Wegovy. While these custom medications emerged during a past shortage, the FDA declared the semaglutide shortage resolved in February 2025, making FDA-approved options readily available again. The use of compounded semaglutide presents potential risks due to unverified ingredients, possible contamination, and dosage inaccuracies.

Unlike FDA-approved semaglutide injections which are pre-filled pens, compounded versions often come in vials requiring syringe measurement, increasing the chance of errors. Furthermore, compounded semaglutide is available in various forms such as sublingual drops or nasal sprays, for which clinical studies on safety and effectiveness are lacking. Concerns also exist regarding the use of semaglutide salts and ingredients sourced from unauthorized or nonpharmaceutical facilities.

Individuals considering compounded semaglutide should prioritize pharmacies with proper accreditation and licensing, ensuring they can speak with a pharmacist about the medication. These products always require a prescription, and claims of being "generic" alternatives are misleading. Consulting a healthcare provider is essential for transitioning to FDA-approved semaglutide or discussing any concerns about compounded versions.